Generic pharmaceutical business Amerigen Pharmaceuticals Limited reported on Wednesday the receipt of final approval from the US Food and Drug Administration for the Abbreviated New Drug Application (ANDA) for Penicillamine Capsules USP in 250 mg.
According to the company, Penicillamine Capsules USP are indicated in the treatment of Wilson's disease, cystinuria as well as in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.
This is the first ANDA to be approved as a generic equivalent to Bausch Heath's Cuprimine, Amerigen said.
In the US, the Penicillamine Capsules USP in 250 mg has already been launched by the company's affiliate, Amerigen Pharmaceuticals Inc.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca